First approved in 1989, clozapine is the only medication indicated for treatment-resistant schizophrenia. It's also indicated ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Morgan Stanley has upgraded Cytokinetics (CYTK) to overweight from equal weight while lowering its price target. Read more ...

Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

It was also decided that henceforth, if any drug with inpatient-applicable REMS ... available in case of an audit by the APPRISE program. REMS requirements for ESAs also stipulate that patients ...

Morgan Stanley (NYSE:MS) analyst Jeffrey Hung upgraded Cytokinetics (NASDAQ:CYTK) stock from Equalweight to Overweight, while ...

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

In order to bring it to market, a special program called Risk Evaluation and Mitigation Strategy (REMS) had to be put in place, where only eligible patients could access the drug through a very ...

Your patient presents with pain, swelling and impaired knee function. One rare diagnosis is non-malignant tenosynovial giant ...

A plan for the US Food and Drug Administration to propose banning formaldehyde and certain formaldehyde-releasing chemicals from being used in hair-straightening products remains in limbo under ...